Significant tumor regression was observed following treatment with CDK2 siRNA when combined with palbociclib compared with palbociclib treatment alone (p = 0.035) or the control siRNA treatment group (p = 0.012) (Figure 6B, C). This evidence concerns the gene CDK2 and neoplasm.